Overview

Short Benznidazole Regimen for Chronic Phase Chagas Disease Patients

Status:
WITHDRAWN
Trial end date:
2026-10-30
Target enrollment:
Participant gender:
Summary
Multicentric study on Chagas disease that seeks to evaluate a new treatment regimen using the drug benznidazole. Currently, existing treatment regimens are long and have frequent side effects, which leads to a high dropout rate among patients. The research proposes testing two shorter benznidazole regimens to see if they are as effective as standard treatment, but with fewer side effects. The study will have 672 participants and will be carried out in four locations, Bolivia and Colombia. The objective is to analyze the efficacy and safety of new treatment regimens, evaluating the parasitological response in comparison with standard treatment. In addition, an economic assessment will be carried out to analyze direct and indirect costs, including procedures associated with the management of adverse events.
Phase:
PHASE3
Details
Lead Sponsor:
Evandro Chagas Institute of Clinical Research
Collaborator:
Andrea Silvestre de Sousa
Treatments:
benzonidazole